R-METHUCSF 在白癜风患者中的 I-II 期安全性和疗效-猫眼课题宝

R-METHUCSF 在白癜风患者中的 I-II 期安全性和疗效

批准号：

6245275

负责人：

JOSEPH G MORELLI

金额：

$2.65万

依托单位：

UNIVERSITY OF COLORADO DENVER

依托单位国家：

美国

项目类别：

财政年份：

1997

资助国家：

美国

项目状态：

已结题

起止时间：

1997-02-14 至 1997-11-30

来源：

https://reporter.nih.gov/project-details/6245275

关键词：

clinical research clinical trial phase I colony stimulating factor drug screening /evaluation human subject human therapy evaluation melanins melanocyte photosensitizing agents recombinant proteins skin disorder chemotherapy vitiligo

项目摘要

项目成果

JOSEPH G MORELLI的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

Vitiligo is a disorder in which there is a loss of melanocytes particularly in areas of the skin. Repigmenttion of an area of vitiligo has been difficult with standard treatment modalities resulting in success rates between 30-50%. Recombinant-methuscf has been found to exert a positive effect on human melanocyte activity. The goal of therapy in vitiligo is to repopulate an affected area of skin with functioning melanocytes. The use of r-metHuSCF to accomplish this seems reasonable because of the possibility of stimulating melanocytes into the affeected area from the margins of a lesion or from the hair follicles and/or stimulation of these melanocytes to produce more melanin with resultant repigmentation.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文